IRCT20180612040068N1.

Methods	Trial design: triple‐blind RCT with 3 parallel arms; only 2 arms relevant; the other arm investigate metronidazol Type of record: trial register entry Sample size: 135 Setting: inpatient Country: Iran Language: English Number of centres: 1 Study purpose (treatment, prevention): treatment Trial registration number: IRCT20180612040068N1 Date of registration: 19 April 2021
Participants	Inclusion criteria Hospitalized patient with positive SARS‐CoV‐2 test > 18 years old Willing to participate in the study Exclusion criteria Allergic history to metronidazole or ivermectin or hypersensitivity reaction to them during trial Pregnant patients COPD patients suspected of ILD Long history of diabetes Cirrhotic patients Epileptic patients Patients with severe renal failure and GFR < 20 mL/min Participating in another RCT
Interventions	Details of intervention Type and dose: ivermectin, once daily (weight‐adjusted) Route of administration: oral Treatment details of control group No treatment except standard of care Concomitant therapy: standard of care (no details provided) administered in all study arms
Outcomes	Primary study outcome Length of time to recover from shortness of breath Length of time to not require oxygen Reduction of CRP Normalization of lymphopenia, measured by specialists Length of hospital stay Likelihood of admission to ICU Likelihood of mortality Relevant review outcomes planned Likelihood of admission to ICU Likelihood of mortality Additional study outcomes None
Notes	Reason for awaiting classification: study completed, but results not published yet Recruitment status: completed Prospective completion date: April 2021, study completed Planned completion date more than 6 months ago: yes Date last update posted: 19 April 2021 Sponsor/funding: Shiraz University of Medical Sciences